Also, we show performance comparison of the iSEND groups with different PD-L1 expression-level groups to discuss potential clinical implications of the iSEND model in advanced NSCLC patients treated with PD-1/L1 monotherapy. Here, CD274 is linked to non-small cell lung carcinoma.